Yalda Nahidi; Naser Tayyebi Meibodi; Farahnaz Abdolhosseinzadeh; Mostafa Izanlu; Sima Davoodi
Abstract
Background: Psoriasis is a chronic inflammatory skin disease with extensive systemic effects. The role of sex hormones in the pathogenesis of psoriasis remains unknown. Therefore, in this study, the level of sex hormones in male chronic plaque psoriasis patients was evaluated.Methods: This study was ...
Read More
Background: Psoriasis is a chronic inflammatory skin disease with extensive systemic effects. The role of sex hormones in the pathogenesis of psoriasis remains unknown. Therefore, in this study, the level of sex hormones in male chronic plaque psoriasis patients was evaluated.Methods: This study was descriptive-analytic of the cross-sectional type, done with a total population of 60, including 30 patients with chronic plaque psoriasis and 30 healthy subjects in the control group. Serum levels of testosterone, estradiol, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured in patients and the control group who did not have psoriasis. The two groups were matched based on the grouped matching technique. The two groups were matched for age (34 ± 9 years) and BMI (30 ± 3 kg/m2), and the effects of these two variables on hormonal levels were eliminated. According to the results of the Kolmogorov-Smirnov test, the data had a normal distribution. The independent t-test and Pearson correlation coefficient were used for data analysis. A P-value less than 0.05 was considered significant.Results: The levels of LH and FSH were significantly higher in the patient group than in the healthy group (P = 0.01 and P < 0.001, respectively). Testosterone and estradiol serum levels were lower in the patient group than in the healthy group (P < 0.001).Conclusion: Our study suggests that male patients with chronic plaque psoriasis have higher levels of LH and FSH and lower levels of testosterone and estradiol than the general male population.
Yalda Nahidi; Naser Tayyebi Meibodi; Amir Hossein Jafarian; Habibollah Esmaily; Elham Pishnamaz
Abstract
Background: Radiation-induced basal cell carcinoma (BCC) can be multiple, large, and recurring, which complicates its treatment in some cases. According to reports on the role of cyclooxygenase 2 (COX2) inhibitors in the treatment or prevention of non-melanoma skin cancers and considering ...
Read More
Background: Radiation-induced basal cell carcinoma (BCC) can be multiple, large, and recurring, which complicates its treatment in some cases. According to reports on the role of cyclooxygenase 2 (COX2) inhibitors in the treatment or prevention of non-melanoma skin cancers and considering the fact that COX2 expression has not been evaluated in radiation-induced basal cell carcinoma, weset out to assess the expression of COX2 in these lesions. Methods: In this study, COX2 expression was assessed by immunohistochemistry using anti-COX2 antibody on paraffinembedded blocks of 86 patients referred to Emam Reza Hospitalin Mashhad with BCC diagnosis by pathological examination (43 patients with and 43 without a history of radiotherapy) followed by semi-quantitative evaluation of COX2. Results: In our study, COX2 expression score was significantly higher in patients with a history of radiotherapy than those without radiotherapy (P<0.001). No correlation was found between theintensity and percentage of staining with sex, age, site of lesion, recurrence, and pathology of the tumor. Conclusion: Given the higher expression level of COX2 in the radiation-induced BCC patients, the use of COX2 inhibitors in these individuals may be effective in the incidence, recurrence, or treatment of BCC.